Table 4. Characteristics of patients receiving plasma exchange therapy.

	Total (n = 12)	T2 lesion (n = 10)	Gd+ (n = 7)
Isolated ON	2 (16.7%)	1 (10.0%)	1 (14.3%)
Clinically isolated syndrome	3 (25.0%)	2 (20.0%)	2 (28.6%)
Definite multiple sclerosis (2010 revision of the McDonald criteria)	7 (58.3%)	7 (70.0%)	4 (57.1%)
Swanton positive	6 (50.0%)	6 (60.0%)	5 (71.4%)
Swanton negative	6 (50.0%)	4 (40.0%)	2 (28.6%)
Mean visual acuity pre treatment	0.22 ± 0.10 SEM	0.16 ± 0.08 SEM	0.11 ± 0.04 SEM
Mean visual acuity post treatment	0.53 ± 0.07 SEM	0.24 ± 0.07 SEM	0.22 ± 0.06 SEM
Mean VEP P100 latency of affected eye pre treatment	104.9 ms ± 15.9 SEM	103.2 ms ± 17.4 SEM	131.6 ms ± 2.9 SEM
Mean VEP P100 amplitude of affected eye pre treatment	2.3 µV ± 0.6 SEM	2.1 µV ± 0.7 SEM	2.4 µV ± 0.8 SEM
Mean VEP P100 latency of affected eye post treatment	123.0 ms ± 4.5 SEM	125.0 ms ± 4.8 SEM	124.5 ms ± 7.3 SEM
Mean VEP P100 amplitude of affected eye post treatment	4.8 µV ± 1.2 SEM	5.3 µV ± 1.4 SEM	6.1 µV ± 1.8 SEM